What role does azacitidine play in regulating gvhd associated histone changes?

Why does azacitidine affect histone changes in GVHD?

Azacitidine is a DNA methyltransferase inhibitor. It works by incorporating into DNA during cell division and binding irreversibly to DNMT enzymes, which reduces DNA methylation. Reduced DNA methylation can lead to changes in chromatin structure that influence histone modifications. In GVHD, this indirect effect on chromatin may help restore normal gene expression patterns disrupted by the immune attack on host tissues.

Does azacitidine reverse histone acetylation or methylation marks in GVHD?

Azacitidine does not directly reverse specific histone marks like acetylation or methylation. Its primary action is on DNA methylation. Any observed changes in histone modifications are secondary effects from altered gene activation or repression. In GVHD models, azacitidine has shown effects on T-cell subsets that may indirectly stabilize or alter histone states through changes in transcription factor binding.

What clinical data exist on azacitidine for GVHD-associated histone changes?

No clinical studies have directly measured histone modifications in patients treated with azacitidine for GVHD. Clinical reports focus on azacitidine’s use as a bridge to transplant or as a maintenance therapy after transplant to prevent relapse. Data on its use in established GVHD are limited and mostly from small series or single-center reports.

How does azacitidine compare with vorinostat or other HDAC inhibitors in GVHD?

Azacitidine is a hypomethylating agent, hypomethylating agents work differently than HDAC inhibitors such as vorinostat. HDAC inhibitors directly increase histone acetylation. Azacitidine’s effect on histone changes is only secondary. Clinical trials comparing the two classes of drugs for GVHD are scarce.